Answers are grounded in this paper and cite their sources.
In vitro study demonstrates that certain plant extracts block thyrotropin binding and adenylate cyclase stimulation in human thyroid membranes, indicating hormone adduct formation.
The present studies were undertaken to explore the mechanism by which, as previous studies have shown, freezedried aqueous extracts (FDE) of plants of the species Lycopus virginicus and Lycopus europaeus, Melissa officinalis (Laminaceae), and Lithospermum officinale (Boraginaceae) have the ability to inhibit at least many of the effects of exogenous and endogenous TSH on the thyroid gland. To this end, we have examined the in vitro effects of FDE from these plants on the ability of bovine TSH (bTSH) to both bind to human thyroid plasma membranes (TPM) and activate adenylate cyclase therein. FDE of these four species produced a dose-related, ultimately complete, inhibition of the binding of 125I-labeled bTSH when studied at 4 C in a 20 mm Tris-HCl-0.5% BSA buffer, pH 7.45. Half-maximum inhibition of bTSH binding was produced by approximately 50 mU/ml bTSH and only about 10-30 μg/ml of the four active FDE. When studied in Tris-BSA-50 mm NaCl buffer at 37 C, these FDE remained inhibitory to bTSH binding, but their potency was decreased to about one fifth of that seen in the absence of NaCl. The binding of [125I]hCG to rat testis membranes was also inhibited by all of these FDE, but no effect on the binding of [125I]insulin to crude rat liver membranes was observed. In concentrations as high as 1 mg/ml, FDE of Verbena officinalis (Verbenaceae), which belongs to the same order (Tubiflorae) as the other plants, but exhibits no antithyrotropic or antigonadotropic activity in vivo, had no effect on either the binding of bTSH to thyroid membranes or the binding of hCG to rat testis membranes. No inhibition of [125I]bTSH binding occurred when TPM were preincubated with the four active FDE, washed, and then incubated with [125I]bTSH in medium devoid of FDE. Hence, the inhibition of [125I]bTSH binding seen when labeled hormone and active FDE were added together was not due to irreversible binding of FDE to TPM or damage to the TSH receptor. When [125I]bTSH was incubated with the active FDE in Tris-BSA and the mixture was chromatographed on Sephadex G-100 using the same buffer, [125I]bTSH was shifted from an apparent mol wt of 30,000 and eluted at the void volume. Direct binding of [125I]bTSH in fractions from the new, large molecular peak was nil. Addition of a large excess of unlabeled bTSH during preincubation prevented the shift in the elution pattern of [125I] bTSH produced by these FDE. When the same experiment was performed in the presence of 50 mm NaCl, only about half of the [125I]bTSH eluted at the void volume, whereas the remainder eluted in a position identical to that of [125I]bTSH alone. We also assessed the effects of those FDE with antithyrotropic activity on the adenylate cyclase response to bTSH in a human thyroid particulate fraction. At concentrations of 20 or 40 μg/ml, FDE did not affect basal adenylate cyclase activity, but inhibited the stimulatory effect of 4 mU bTSH/ml from 26–43%. At a much higher concentration (200 μg/ml), FDE decreased both basal and bTSH-stimulated accumulation of cAMP by as much as 80%. These results indicate that some as yet undefined component(s) of the active FDE forms an adduct with bTSH, making the hormone unable to bind to its receptor; presumably, this explains the ability of FDE to inhibit the activation of adenylate cyclase that bTSH induces. These effects appear sufficient to account for the antithyrotropic actions of FDE previously demonstrated in vivo. Similarly, the ability of FDE to inhibit the binding of hCG to rat testis could explain the demonstrated ability of FDE to exert an antigonadotropic action. (Endocrinology115: 527–534, 1984)
No takes yet. Share an insight, caveat, or question.
Aufmkolk et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: